Reducing circRNA Manufacturing Costs Through Enzyme-Free Purification, Higher Yield & Scalable Processing
1:00 pm - Thursday 18th February 2027
- Replacing reliance on RNase R, where GMP-scale supply can present cost and scalability constraints, with proprietary column chromatography to simplify circRNA processing and reduce product loss
- Increasing recovery to approximately 85% and achieving around 95% purity while scaling manufacturing towards clinical production volumes
- Scaling an enzyme-free purification process from GMP toxicology material towards 30-50 g production while maintaining yield, purity and process simplicity
- Connecting higher yield, simpler purification and lower cost of goods with more affordable RNA therapeutics and broader patient access
